RNS Number : 0988D
OptiBiotix Health PLC
01 March 2022

OptiBiotix Health plc
("OptiBiotix" or the "Company")

Commercial Appointments

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, blood pressure, diabetes, announces the following appointments[1]: Zac Sniderman as Business Development & Sales Director North America, Shiraz Butt as E-Commerce Director and Karl Burkitt as Marketing Director.

Zac brings a broad experience developing a food and supplement ingredient businesses in North America working for Galenicum Speciality Ingredients, Jarrow Formulas and Best Ground International. He has an entrepreneurial mindset and an extensive network. He will focus on the development of ingredient sales to brand owners and contract manufacturers for both pro- and prebiotics in close cooperation with our established partners.

Shiraz has successfully developed the e-commerce businesses for a range of companies, such as PhD (now part of Science In Sports) and Iovate Health Sciences. He has built digital sales from the ground up into significant contributors to the success of the companies he has worked for. Shiraz will focus on developing the untapped e-commerce potential of our pro- and prebiotic brands such as SlimBiome Medical, Go-Figure and CholBiome.

Karl Burkitt has a rich career in which he developed and led the marketing and business development function in various branded and ingredient businesses, such as Novartis Consumer Health, Kerry Ingredients & Flavours and AB Mauri. Karl will lead our marketing function, on a part time basis, and work closely with the pro- and prebiotic commercial divisions on developing ingredient and consumer sales.

The above appointments expand the capabilities of our management team in line with our commercial strategy, which is to further expand ingredient sales, particularly in the large North American market, whilst developing our final product sales containing our unique ingredients.

René Kamminga, CEO of OptiBiotix Ltd, commented: *"In the past 12 months we have established the credibility and brand awareness of our science-based ingredients SlimBiome®, OptiBiome, LeanBiome and LP_{LDL}® ingredients, significantly growing sales to a wider number of reputable global brands in multiple markets. These appointments are a further investment to accelerate the growth of the Company and to broaden and deepen our income streams with a particular focus on North America and E-Commerce."*

[1]These appointments are non-statutory director appointments in the Company or its subsidiaries.

For further information, please contact:

OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive *Contact via Walbrook below*

Cenkos Securities plc (Broker) Tel: 020 7397 8900
Callum Davidson / Neil McDonald
Michael Johnson / Russell Kerr (Sales)

Walbrook PR Ltd Mob: 07407 804 654
Alice Woodings

This communication is a "Reach" announcement. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRATPMRTMTJTBAT